NO990912L - Terapeutiske kombinasjoner av PAR-antagonister og RXR-agonister og bruken derav - Google Patents

Terapeutiske kombinasjoner av PAR-antagonister og RXR-agonister og bruken derav

Info

Publication number
NO990912L
NO990912L NO990912A NO990912A NO990912L NO 990912 L NO990912 L NO 990912L NO 990912 A NO990912 A NO 990912A NO 990912 A NO990912 A NO 990912A NO 990912 L NO990912 L NO 990912L
Authority
NO
Norway
Prior art keywords
antagonist
rar
therapeutic combinations
rxr agonists
antagonists
Prior art date
Application number
NO990912A
Other languages
English (en)
Norwegian (no)
Other versions
NO990912D0 (no
Inventor
Pierre Chambon
Hinrich Gronemeyer
Peter R Reczek
Jacek Ostrowski
Original Assignee
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Univ Pasteur
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Centre Nat Rech Scient, Univ Pasteur, Bristol Myers Squibb Co filed Critical Inst Nat Sante Rech Med
Publication of NO990912D0 publication Critical patent/NO990912D0/no
Publication of NO990912L publication Critical patent/NO990912L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO990912A 1996-08-28 1999-02-25 Terapeutiske kombinasjoner av PAR-antagonister og RXR-agonister og bruken derav NO990912L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2477296P 1996-08-28 1996-08-28
PCT/US1997/015155 WO1998008546A2 (fr) 1996-08-28 1997-08-28 Combinaisons therapeutiques d'antagonistes de rar et d'agonistes de rxr

Publications (2)

Publication Number Publication Date
NO990912D0 NO990912D0 (no) 1999-02-25
NO990912L true NO990912L (no) 1999-04-27

Family

ID=21822317

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990912A NO990912L (no) 1996-08-28 1999-02-25 Terapeutiske kombinasjoner av PAR-antagonister og RXR-agonister og bruken derav

Country Status (11)

Country Link
US (2) US6130230A (fr)
EP (1) EP0928200B1 (fr)
JP (1) JP2001500486A (fr)
AT (1) ATE236654T1 (fr)
AU (1) AU731060B2 (fr)
CA (1) CA2263817A1 (fr)
DE (1) DE69720745T2 (fr)
ES (1) ES2196361T3 (fr)
IL (1) IL128723A0 (fr)
NO (1) NO990912L (fr)
WO (1) WO1998008546A2 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1117762A4 (fr) 1998-09-29 2004-02-25 Gamida Cell Ltd Procedes de regulation de la proliferation et de la differentiation de cellules souches et precurseurs
CA2254429A1 (fr) * 1998-11-19 2000-05-19 Tully Michael Underhill Compositions favorisant la chondrogenese
WO2000061233A2 (fr) * 1999-04-14 2000-10-19 Allergan Sales, Inc. Methodes et compositions de traitement et de prevention de maladies pulmonaires
US6436993B1 (en) * 1999-07-13 2002-08-20 The Salk Institute For Biological Studies Use of RAR antagonists as modulators of hormone mediated processes
EP1265637A2 (fr) * 2000-03-14 2002-12-18 The University Of Western Ontario Compositions et procedes exer ant un effet sur l'osteogenese
WO2001078700A2 (fr) * 2000-04-13 2001-10-25 Frederic Geissmann Compositions et procedes utilises pour moduler la fonction du systeme immunitaire
CA2410480A1 (fr) * 2000-05-26 2001-12-06 Board Of Trustees Of The University Of Illinois Reactifs et methodes destines a l'identification et a la modulation de l'expression de genes regules par les retinoides
US6713515B2 (en) 2000-09-13 2004-03-30 Bristol Myers Squibb Company Retinoic acid receptor antagonists as promoters of angiogenesis
US20030008273A1 (en) * 2001-06-11 2003-01-09 Thomas Perlmann Methods for increasing the survival of neuronal cells
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (fr) 2002-01-25 2006-06-07 Gamida Cell Ltd Methodes de developpement de cellules souches et de cellules precurseurs, populations de cellules multipliees obtenues a l'aide de ces methodes
US20040097587A1 (en) * 2002-03-27 2004-05-20 Arbiser Jack L Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
US20050054731A1 (en) * 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US20050112123A1 (en) * 2003-10-06 2005-05-26 Vaughan Michael R. Methods of treating proteinuria
GB2411115A (en) * 2004-02-19 2005-08-24 Medical Res Council Retinoic acid antagonists for the treatment of oesophageal disorders
WO2006030442A2 (fr) 2004-09-16 2006-03-23 Gamida-Cell Ltd. Methodes de culture ex vivo de cellules souches et de precurseur par co-culture avec des cellules mesenchymales
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP2181710A1 (fr) * 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands pour la modulation de l'activité du récepteur gamma orphelin (NR1F3)
EP2329817A1 (fr) * 2009-09-04 2011-06-08 Ernst-Moritz-Arndt-Universität Greifswald Antagonistes du récepteur de l'acide rétinoïque, inhibiteurs de miR-10a et inhibiteurs des répresseurs HOXB1 et/ou HOXB3 pour le traitement du cancer du pancréas
RU2678561C9 (ru) 2011-06-24 2019-03-05 ДжиАрАй Био, Инк. Предупреждение и лечение воспалительных состояний
CN104204192A (zh) 2012-02-13 2014-12-10 加米达细胞有限公司 间充质干细胞调理的基质及其产生和使用方法
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
WO2015026990A2 (fr) 2013-08-20 2015-02-26 University Of Washington Through Its Center For Commercialization Nouveaux inhibiteurs spécifiques de l'hydrolase d'acide rétinoïque cytochrome p450 26
EP3380086B1 (fr) 2015-11-25 2021-10-13 IO Therapeutics, Inc. Agonistes sélectifs de rar-alpha, résistants à cyp26, dans le traitement du cancer
EP3468600A4 (fr) * 2016-06-10 2019-11-13 IO Therapeutics, Inc. Composés rétinoïdes et rexinoïdes sélectifs du récepteur et modulateurs immunitaires pour l'immunothérapie du cancer
CA3069676A1 (fr) * 2017-07-13 2019-01-17 Io Therapeutics, Inc. Composes retinoides et rexinoides immunomodulateurs en combinaison avec des modulateurs immunitaires pour l'immunotherapie du cancer
NZ761401A (en) 2017-08-31 2022-11-25 Io Therapeutics Inc Rar selective agonists in combination with immune modulators for cancer immunotherapy
US20220031644A1 (en) * 2020-07-31 2022-02-03 The Trustees Of Columbia University In The City Of New York Method of treating adenoid cystic carcinoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016658A1 (fr) 1991-03-18 1992-10-01 The Salk Institute For Biological Studies Compositions a elements de reaction et dosages les incorporant
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5399586A (en) * 1993-03-11 1995-03-21 Allergan, Inc. Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
JPH08504104A (ja) * 1993-05-18 1996-05-07 アンスティテュー・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル レチノイン酸レセプター蛋白をコード化する遺伝子における改変を含む遺伝子工学的マウス
US5702914A (en) * 1994-12-21 1997-12-30 The Salk Institute For Biological Studies Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements
US5747661A (en) * 1995-01-13 1998-05-05 Howard Hughes Medical Institute Retinoid-inducible response elements
AU4530496A (en) 1995-01-13 1996-07-31 Salk Institute For Biological Studies, The Allosteric control of nuclear hormone receptors
US5559248A (en) * 1995-04-05 1996-09-24 Bristol-Myers Squibb Co. Retinoid-like heterocycles
US6025388A (en) * 1995-04-26 2000-02-15 Allergan Sales, Inc. Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US5906920A (en) 1995-08-29 1999-05-25 The Salk Institute For Biological Studies Methods for the detection of ligands for retinoid X receptors
WO1998029120A1 (fr) 1996-12-31 1998-07-09 The Salk Institute For Biological Studies Traitement des liposarcomes par l'utilisation d'une association de thiazolidinediones et d'agonistes selectifs de recepteurs retinoïde x
US6646008B1 (en) 1996-12-31 2003-11-11 The Salk Institute For Biological Studies Treatment of disease states which result from neoplastic cell proliferation using PPAR-γ activators and compositions useful therefor
US6387673B1 (en) 1997-05-01 2002-05-14 The Salk Institute For Biological Studies Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds

Also Published As

Publication number Publication date
ATE236654T1 (de) 2003-04-15
DE69720745D1 (de) 2003-05-15
AU4167497A (en) 1998-03-19
ES2196361T3 (es) 2003-12-16
WO1998008546A2 (fr) 1998-03-05
NO990912D0 (no) 1999-02-25
US6130230A (en) 2000-10-10
EP0928200A2 (fr) 1999-07-14
CA2263817A1 (fr) 1998-03-05
EP0928200B1 (fr) 2003-04-09
IL128723A0 (en) 2000-01-31
DE69720745T2 (de) 2004-02-26
JP2001500486A (ja) 2001-01-16
US6653322B1 (en) 2003-11-25
WO1998008546A3 (fr) 1998-04-23
AU731060B2 (en) 2001-03-22
WO1998008546A8 (fr) 2001-04-19

Similar Documents

Publication Publication Date Title
NO990912L (no) Terapeutiske kombinasjoner av PAR-antagonister og RXR-agonister og bruken derav
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
ATE258067T1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
CY1124763T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της πρωτοπαθους αϋπνιας
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
SE9803710D0 (sv) Use of certain drugs for treating nerve root injury
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
EA199900137A1 (ru) Замещенные пиридины в качестве избирательных ингибиторов циклооксигеназы-2
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60331537D1 (de) Kombinationen zur behandlung von multiplem myelom
BR0008847A (pt) Composições analgésicas que compreendemcompostos antiepilépticos, e métodos de uso dasmesmas
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
ES2165990T3 (es) Thip para el tratamiento de trastornos del sueño.
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
DK0415613T3 (da) Anvendelse af sertralin til behandling af præmatur ejakulation
TWI367751B (en) Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
CA2156481A1 (fr) Compositions antagonistes du recepteur 5-ht2, utiles pour le traitement des troubles veineux
IT1269185B (it) Associazione dotata di effetto sinergico che ha un effetto antagonista dei recettori nk1 e nk2
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
DK0768083T3 (da) Anvendelse af sertralin til at behandle patienter med post myocardisk infarkt
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application